RESUMO
The treatment of reflux disease did not changed. PPI treatment remains the first line treatment and surgery a second line treatment. The effect of surgery in reflux disease reduces and, after ten years, a part of the operated patients needs PPI again. The triple therapy is the treatment of choice of Helicobacter pylori infection. Patients with persistent Helicobacter pylori infection, after a first treatment, should be treated with a sequential treatment. PPI are effective in the prevention of gastroduodenal lesions and in the treatment of dyspeptic symptoms during NSAID treatment. IPP should be given to all patients presenting dyspeptic symptoms under NSAID or COX-2 administration.
Assuntos
Esofagite Péptica/terapia , Refluxo Gastroesofágico/terapia , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori , Esofagite Péptica/tratamento farmacológico , Refluxo Gastroesofágico/tratamento farmacológico , Humanos , Gastropatias/tratamento farmacológico , Gastropatias/microbiologiaRESUMO
There are no real therapeutical acquisitions in the year 2006. The latest breakthroughs related to peptic disease treatment are the subject of this article. In particular various therapeutic procedures in reflux disease, including Barrett's oesophagus are developed here. Two important items were emphasized in the treatment of gastric and duodenal ulcers, in particular Helicobacter pylori eradication and the treatment of bleeding ulcer. Prophylaxis of gastrointestinal lesions due to AINS is also approached in detail.